文献速递免疫规划

SARS-CoV-2刺突蛋白中显性CD8+CTL表位的鉴定

Identification of a dominant CD8+ CTL epitope in the SARS-associated coronavirus 2 spike protein.
PubMed 文献 · Vaccine · 2020-10-19

本研究以BALB/c小鼠为模型,用SARS-CoV-2刺突蛋白受体结合域(RBD)重组蛋白免疫,通过表位肽刺激和干扰素-γ检测筛选CD8+ T细胞表位。结果显示S-RBD特异性CD8+ T细胞识别H2-Dd限制性S526-533肽段,该动物模型适用于评估SARS-CoV-2疫苗免疫原性。

要点

  • 鉴定出H2-Dd限制性S526-533为SARS-CoV-2 S蛋白CD8+ CTL表位。
  • BALB/c小鼠RBD免疫模型可检测S特异性CD8+ T细胞应答。
  • 该模型适用于评估SARS-CoV-2疫苗的细胞免疫原性。

核心结论

  • SARS-CoV-2 S蛋白中存在H2-Dd限制性S526-533 CD8+ CTL表位,可用于测量针对该蛋白的细胞免疫应答。
  • 该BALB/c小鼠动物模型适合评估SARS-CoV-2疫苗的免疫原性。

研究设计与样本

  • 以SARS-CoV-2 S蛋白受体结合域(RBD)重组蛋白免疫BALB/c小鼠。
  • 用预测的CTL表位肽刺激并检测干扰素-γ产生以检测S-RBD特异性CD8+ T细胞。
  • 通过肽段截短确定被识别的表位。

主要发现

  • S-RBD特异性CD8+ T细胞识别H2-Dd限制性S526-533肽段。

临床怎么用

  • 该动物模型可用于SARS-CoV-2疫苗免疫原性评价中细胞免疫应答的检测。
  • S526-533表位可用于测量针对SARS-CoV-2 S蛋白的CD8+ T细胞应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Coronavirus disease 2019 (COVID-19), which is caused by SARS-CoV-2, has been spreading throughout the world. To date, there are still no approved human vaccines for this disease. To develop an effective vaccine, the establishment of animal models for evaluating post-vaccination immune responses is necessary. In this study, we have identified a CTL epitope in the SARS-CoV-2 spike (S) protein that could be used to measure the cellular immune response against this protein. Potential predicted CTL epitopes of the SARS-CoV-2 S protein were investigated by immunizing BALB/c mice with a recombinant of the receptor-binding domain (RBD) of the S protein. Then, CD8+ T cells specific for S-RBD were detected by stimulating with potential epitope peptides and then measuring the interferon-gamma production. Truncation of this peptide revealed that S-RBD-specific CD8+ T cells recognized a H2-Dd-restricted S526-533 peptide. In conclusion, this animal model is suitable for evaluating the immunogenicity of SARS-CoV-2 vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Muraoka D, Situo D, Sawada SI, et al. Identification of a dominant CD8+ CTL epitope in the SARS-associated coronavirus 2 spike protein. Vaccine. 2020. PMID: 33164796. doi:10.1016/j.vaccine.2020.10.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。